Vicky Hsu

1.2k total citations
12 papers, 960 citations indexed

About

Vicky Hsu is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Vicky Hsu has authored 12 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Oncology. Recurrent topics in Vicky Hsu's work include Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Vicky Hsu is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Vicky Hsu collaborates with scholars based in United States, Sweden and Canada. Vicky Hsu's co-authors include Ping Zhao, Vikram Sinha, Christian Wagner, Joseph A. Grillo, Yuzhuo Pan, S-M Huang, Y. Pan, Kellie S. Reynolds, Lei Zhang and Rosane Charlab and has published in prestigious journals such as Clinical Cancer Research, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Vicky Hsu

12 papers receiving 949 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Vicky Hsu 380 304 231 196 130 12 960
Vijay Upreti 491 1.3× 328 1.1× 206 0.9× 403 2.1× 199 1.5× 55 1.7k
Huang Sm 329 0.9× 359 1.2× 213 0.9× 208 1.1× 120 0.9× 26 1.1k
Inna Y. Gong 507 1.3× 281 0.9× 125 0.5× 109 0.6× 102 0.8× 51 1.4k
Cristi R. King 564 1.5× 538 1.8× 172 0.7× 379 1.9× 102 0.8× 17 1.2k
Erica L. Woodahl 332 0.9× 380 1.3× 219 0.9× 213 1.1× 92 0.7× 41 992
Takenori Niioka 320 0.8× 202 0.7× 220 1.0× 166 0.8× 105 0.8× 72 1.0k
Satjit Brar 282 0.7× 198 0.7× 114 0.5× 158 0.8× 86 0.7× 15 838
Kenichi Umehara 487 1.3× 393 1.3× 213 0.9× 193 1.0× 74 0.6× 52 908
Alice Ke 208 0.5× 228 0.8× 240 1.0× 138 0.7× 80 0.6× 30 755

Countries citing papers authored by Vicky Hsu

Since Specialization
Citations

This map shows the geographic impact of Vicky Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicky Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicky Hsu more than expected).

Fields of papers citing papers by Vicky Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicky Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicky Hsu. The network helps show where Vicky Hsu may publish in the future.

Co-authorship network of co-authors of Vicky Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Vicky Hsu. A scholar is included among the top collaborators of Vicky Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicky Hsu. Vicky Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Chow, Edwin C.Y., Alexei Ionan, Shwu‐Luan Lee, et al.. (2024). FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation. Clinical Cancer Research. 30(19). 4266–4271. 2 indexed citations
2.
Chang, Elaine, Chana Weinstock, Lijun Zhang, et al.. (2020). FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(4). 922–927. 135 indexed citations
3.
Norsworthy, Kelly J., Lola Luo, Vicky Hsu, et al.. (2019). FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Clinical Cancer Research. 25(11). 3205–3209. 102 indexed citations
4.
Hsueh, Chia‐Hsiang, Vicky Hsu, Yuzhuo Pan, & Ping Zhao. (2018). Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug–Drug Interactions Involving Enzyme Modulation. Clinical Pharmacokinetics. 57(10). 1337–1346. 16 indexed citations
5.
Guo, Yingying, Xiaoyan Chu, Neil Parrott, et al.. (2018). Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clinical Pharmacology & Therapeutics. 104(5). 865–889. 88 indexed citations
6.
Hsu, Vicky, et al.. (2017). PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters. Clinical Pharmacology & Therapeutics. 103(3). 485–492. 66 indexed citations
7.
Pan, Yuzhuo, Vicky Hsu, Manuela Grimstein, et al.. (2016). The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives. The Journal of Clinical Pharmacology. 56(S7). S122–31. 39 indexed citations
8.
Wagner, Christian, Yuzhuo Pan, Vicky Hsu, Vikram Sinha, & Ping Zhao. (2015). Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA. Clinical Pharmacokinetics. 55(4). 475–483. 78 indexed citations
9.
Wagner, Christian, Ping Zhao, Y. Pan, et al.. (2015). Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK. CPT Pharmacometrics & Systems Pharmacology. 4(4). 226–230. 217 indexed citations
10.
Wagner, Christian, Yuzhuo Pan, Vicky Hsu, et al.. (2014). Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration. Clinical Pharmacokinetics. 54(1). 117–127. 119 indexed citations
11.
Hsu, Vicky, Manuela de Lima Toccafondo Vieira, Ping Zhao, et al.. (2013). Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations. Clinical Pharmacokinetics. 53(3). 283–293. 77 indexed citations
12.
Silverstone, Peter H., et al.. (1996). The Prevalence of Major Depressive Disorder and Low Self-Esteem in Medical Inpatients. The Canadian Journal of Psychiatry. 41(2). 67–74. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vijay Upreti Breakdown of academic impact, for papers by Huang Sm Breakdown of academic impact, for papers by Inna Y. Gong Breakdown of academic impact, for papers by Cristi R. King Breakdown of academic impact, for papers by Erica L. Woodahl Breakdown of academic impact, for papers by Takenori Niioka Breakdown of academic impact, for papers by Satjit Brar Breakdown of academic impact, for papers by Kenichi Umehara Breakdown of academic impact, for papers by Alice Ke
Rankless by CCL
2026